Mystery Rozerem ads earn brand infamy

Share this article:
Rozerem reminder ad.
Rozerem reminder ad.

Takeda's Rozerem took top honors in a UK consumer advocacy group's International Bad Product Awards.

London-based Consumers International, which bills itself as a global federation of consumer groups, named the sleeping pill as its worst of the worst on the merits of a 10-second TV reminder ad hawking the drug for school children which ran in September 2006.

The sketchy spot, unrelated to the brand's surreal main “Your Dreams Miss You” campaign, aired only about four times on MSNBC and was disavowed by Takeda and its advertising agencies after an FDA rebuke. Rozerem is not indicated for pediatric use, the spot was not submitted to FDA for vetting and TV reminder ads are a no-no under PhRMA DTC guidelines. Takeda Pharmaceuticals North America is an international affiliate of PhRMA, though the company was not a signatory to those guidelines.

Consumers International said in a release: “This case demonstrates the lengths to which some drug companies will go to increase sales of their products, how direct-to-consumer advertising can promote irrational drug use, and how weak regulation can foster irresponsible corporate behavior.” 

Runners-up included Coca-Cola, for Dasani (“Repackaging tap water”), Kellogg's (“Advertising junk food to kids”) and Mattel, for its handling of a toy recall.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...